Literature DB >> 8896943

Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

J Ducharme1, R Farinotti.   

Abstract

This paper presents the current state of knowledge on chloroquine disposition, with special emphasis on stereoselectivity and microsomal metabolism. In addition, the impact of the patient's physiopathological status and ethnic origin on chloroquine pharmacokinetics is discussed. In humans, chloroquine concentrations decline multiexponentially. The drug is extensively distributed, with a volume of distribution of 200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg when estimated from whole blood data (concentrations being 5 to 10 times higher). Chloroquine is 60% bound to plasma proteins and equally cleared by the kidney and liver. Following administration chloroquine is rapidly dealkylated via cytochrome P450 enzymes (CYP) into the pharmacologically active desethylchloroquine and bisdesethylchloroquine. Desethylchloroquine and bisdesethylchloroquine concentrations reach 40 and 10% of chloroquine concentrations, respectively; both chloroquine and desethylchloroquine concentrations decline slowly, with elimination half-lives of 20 to 60 days. Both parent drug and metabolite can be detected in urine months after a single dose. In vitro and in vivo, chloroquine and desethylchloroquine competitively inhibit CYP2D1/6-mediated reactions. Limited in vitro studies and preliminary data from clinical experiments and observations point to CYP3A and CYP2D6 as the 2 major isoforms affected by or involved in chloroquine metabolism. In vitro efficacy studies did not detect any difference in potency between chloroquine enantiomers but, in vivo in rats, S(+)-chloroquine had a lower dose that elicited 50% of the maximal effect (ED950) than that of R(-)-chloroquine. Stereoselectivity in chloroquine body disposition could be responsible for this discrepancy. Chloroquine binding to plasma proteins is stereoselective, favouring S(+)-chloroquine (67% vs 35% for the R-enantiomer). Hence, unbound plasma concentrations are higher for R(-)-chloroquine. Following separate administration of the individual enantiomers, R(-)-chloroquine reached higher and more sustained blood concentrations. The shorter half-life of S(+)-chloroquine appears secondary to its faster clearance. Blood concentrations of the S(+)-forms of desethylchloroquine always exceeded those of the R(-)-forms, pointing to a preferential metabolism of S(+)-chloroquine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8896943     DOI: 10.2165/00003088-199631040-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  133 in total

1.  Drug interaction of chloroquine with ciclosporin.

Authors:  M R Nampoory; J Nessim; R K Gupta; K V Johny
Journal:  Nephron       Date:  1992       Impact factor: 2.847

2.  THE CIRCULATION IN MALARIA. II. PORTAL ANGIOGRAPHY IN MONKEYS (MACACA MULATTA) INFECTED WITH PLASMODIUM KNOWLESI AND IN SHOCK FOLLOWING MANIPULATION OF THE GUT.

Authors:  M B SKIRROW; T CHONGSUPHAJAISIDDHI; B G MAEGRAITH
Journal:  Ann Trop Med Parasitol       Date:  1964-12

3.  Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography.

Authors:  G Alván; L Ekman; B Lindström
Journal:  J Chromatogr       Date:  1982-04-16

4.  Chloroquine resistance of Plasmodium berghei: biochemical basis and countermeasures.

Authors:  R I Salganik; T G Pankova; T V Chekhonadskikh; T M Igonina
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

5.  Influences of dietary restriction and age on liver enzyme activities and lipid peroxidation in mice.

Authors:  A Koizumi; R Weindruch; R L Walford
Journal:  J Nutr       Date:  1987-02       Impact factor: 4.798

6.  The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects.

Authors:  M Frisk-Holmberg; Y Bergqvist; E Termond; B Domeij-Nyberg
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  The mode of action of chloroquine. Non-weak base properties of 4-aminoquinolines and antimalarial effects on strains of Plasmodium.

Authors:  E Veignie; S Moreau
Journal:  Ann Trop Med Parasitol       Date:  1991-04

8.  Lack of pharmacokinetic interaction between chloroquine and imipramine.

Authors:  C O Onyeji; T A Toriola; F A Ogunbona
Journal:  Ther Drug Monit       Date:  1993-02       Impact factor: 3.681

9.  Chloroquine and desethylchloroquine in plasma, serum, and whole blood: problems in assay and handling of samples.

Authors:  L Rombo; O Ericsson; G Alván; B Lindström; L L Gustafsson; F Sjöqvist
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

10.  Stereoselectivity in the disposition of chloroquine and desethylchloroquine in rabbits.

Authors:  P Augustijns; N Verbeke
Journal:  Arzneimittelforschung       Date:  1992-06
View more
  102 in total

1.  Sensitivity of Plasmodium vivax to chloroquine, mefloquine, artemisinin and atovaquone in north-western Thailand.

Authors:  Moritz Treiber; Gunther Wernsdorfer; Ursula Wiedermann; Kanungnit Congpuong; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2011-09-22       Impact factor: 1.704

Review 2.  [Therapy of tropical diseases after returning from travel].

Authors:  G D Burchard; H Sudeck
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

3.  Is chloroquine making a comeback?

Authors:  Carla Cerami Hand; Steven R Meshnick
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

4.  Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.

Authors:  Pascale M Abena; Eric H Decloedt; Emmanuel Bottieau; Fatima Suleman; Prisca Adejumo; Nadia A Sam-Agudu; Jean-Jacques Muyembe TamFum; Moussa Seydi; Serge P Eholie; Edward J Mills; Oscar Kallay; Alimuddin Zumla; Jean B Nachega
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

5.  Chloroquine-induced QTc prolongation in COVID-19 patients.

Authors:  M P H van den Broek; J E Möhlmann; B G S Abeln; M Liebregts; V F van Dijk; E M W van de Garde
Journal:  Neth Heart J       Date:  2020-04-29       Impact factor: 2.380

6.  Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria.

Authors:  Jens Rengelshausen; Jürgen Burhenne; Margit Fröhlich; Yorki Tayrouz; Shio Kumar Singh; Klaus-Dieter Riedel; Olaf Müller; Torsten Hoppe-Tichy; Walter E Haefeli; Gerd Mikus; Ingeborg Walter-Sack
Journal:  Eur J Clin Pharmacol       Date:  2004-10-13       Impact factor: 2.953

Review 7.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

Authors:  Katherine Winter; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

9.  A comparison of in vitro ADME properties and pharmacokinetics of azithromycin and selected 15-membered ring macrolides in rodents.

Authors:  Astrid Milić; Vlatka Bencetić Mihaljević; Jovica Ralić; Ana Bokulić; Danijela Nožinić; Branka Tavčar; Boris Mildner; Vesna Munić; Ivica Malnar; Jasna Padovan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-10-10       Impact factor: 2.441

10.  High absolute bioavailability of methylene blue given as an aqueous oral formulation.

Authors:  Ingeborg Walter-Sack; Jens Rengelshausen; Heike Oberwittler; Juergen Burhenne; Olaf Mueller; Peter Meissner; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.